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markedly less prevalent in age-matched patients who died 
from sporadic CJD and variant CJD. These results are 
consistent with the hypothesis that Aβ, which can accu-
mulate in the pituitary gland, was present in the inocu-
lated hGH preparations and had a seeding effect in the 
brains of around 50% of all hGH recipients, producing an 
AD-like neuropathology and cerebral amyloid angiopa-
thy (CAA), regardless of whether CJD neuropathology 
had occurred. These findings indicate that Aβ seeding can 
occur independently and in the absence of the abnormal 
prion protein in the human brain. Our findings provide 
further evidence for the prion-like seeding properties of 
Aβ and give insights into the possibility of iatrogenic 
transmission of AD and CAA.
Keywords Amyloid β · Iatrogenic Creutzfeldt–Jakob 
disease · Human growth hormone · Prion protein · Cerebral 
amyloid angiopathy · Neuropathology
Introduction
Prion diseases are transmissible neurodegenerative dis-
orders characterised by the accumulation of a disease-
associated misfolded form of the normal cellular prion 
protein (PrPC) in the central nervous system (CNS), com-
monly referred to as PrPSc [24]. PrPSc is considered to be 
the major, if not the sole, component of the transmissible 
agents known as prions [55]. Unlike other neurodegen-
erative diseases, human prion diseases occur in sporadic, 
genetic and acquired forms [24]. The acquired forms of 
human prion disease include kuru, variant Creutzfeldt–
Jakob disease (vCJD) and iatrogenic Creutzfeldt–Jakob 
disease (iCJD). One of the commonest causes of iCJD 
was treatment with human pituitary-derived growth 
Abstract Human-to-human transmission of Creutzfeldt–
Jakob disease (CJD) has occurred through medical pro-
cedures resulting in iatrogenic CJD (iCJD). One of the 
commonest causes of iCJD was the use of human pitui-
tary-derived growth hormone (hGH) to treat primary or 
secondary growth hormone deficiency. As part of a com-
prehensive tissue-based analysis of the largest cohort yet 
collected (35 cases) of UK hGH-iCJD cases, we describe 
the clinicopathological phenotype of hGH-iCJD in the 
UK. In the 33/35 hGH-iCJD cases with sufficient paraf-
fin-embedded tissue for full pathological examination, 
we report the accumulation of the amyloid beta (Aβ) 
protein associated with Alzheimer’s disease (AD) in the 
brains and cerebral blood vessels in 18/33 hGH-iCJD 
patients and for the first time in 5/12 hGH recipients who 
died from causes other than CJD. Aβ accumulation was 
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hormone (hGH) by intramuscular or subcutaneous injec-
tion in children and young adults with primary or sec-
ondary growth hormone deficiency [8, 64]. Treatment 
with hGH was first associated with iCJD in 1985, since 
when the use of hGH was banned in many countries and 
replacement therapy with biosynthetic growth hormone 
was instigated [19, 34, 54]. Since 1985, over 240 cases 
of iCJD in hGH recipients have been reported in several 
countries [8, 50], with the largest numbers of cases occur-
ring in France (119 cases) and the United Kingdom (UK) 
(78 cases). Although the last case of hGH-iCJD in France 
occurred in 2009 [4], deaths from hGH-iCJD continue to 
occur in the UK, with the most recent death occurring in 
2016, over 30 years since hGH therapy was banned in the 
UK [57, 59].
Other more common neurodegenerative disorders are 
also characterised by the accumulation of abnormal pro-
teins in the CNS, such as amyloid beta (Aβ) and phospho-
tau in Alzheimer’s disease, α-synuclein in Parkinson’s 
disease and TDP-43 in frontotemporal dementia [21]. 
Unlike human prion diseases, there is no current evidence 
to suggest that individual cases of these neurodegenerative 
diseases are acquired [11, 41], but there is an increasing 
body of experimental evidence to indicate that the abnor-
mal protein aggregates in these diseases exhibit prion-like 
properties and can spread through the CNS in a highly 
predictable fashion along well-defined neuroanatomical 
pathways [12, 21, 30, 56, 61, 62]. The term “propagon” 
has recently been proposed for all misfolded multimeric 
proteins that can catalyse the misfolding and aggregation 
of homotypic proteins and lead to the spread of pathologi-
cal misfolding at molecular, tissue, systemic and infectious 
levels [13], with only prions (PrPSc) acting as infectious 
propagons [35]. However, recent reports of Aβ accumula-
tion in the CNS in small numbers of patients with hGH-
iCJD and human dura mater (hDM) graft-related iCJD 
have suggested that Aβ may also have been transmitted 
iatrogenically in these patients [16, 22, 29]. Both the pitui-
tary gland in some patients with Alzheimer’s disease and 
dura mater in elderly individuals can contain aggregates 
of Aβ [28, 36]. There is also evidence of phospho-tau and 
α-synuclein accumulation in the pituitary gland in aging; 
α-synuclein can also be detected in the pituitary gland in 
Parkinson’s disease and Lewy body dementia [23, 25]. 
However, the claim for Aβ transmission in 4/8 UK hGH-
iCJD cases has been questioned in view of the possibility 
of underlying CNS disorders in these patients that might 
predispose to Aβ accumulation, casting “seeds of neuroen-
docrine doubt” [15]. Furthermore, Aβ has been reported 
to co-localise with PrP amyloid deposits in the CNS in 
patients with sCJD and various forms of inherited human 
prion diseases [9, 27, 44, 49], raising further doubts about 
the significance of Aβ deposition in hGH-iCJD.
In order to address these questions, we have undertaken 
a detailed neuropathological, biochemical and genetic study 
of the largest cohort of UK hGH-iCJD cases yet reported, 
comprising 35 cases. The full biochemical and prion pro-
tein genetic data on a subset of 21 cases have been reported 
separately, along with some preliminary neuropathologi-
cal findings [57]. Here, we report the detailed pathological 
findings in both the CNS and a range of non-CNS tissues 
in relation to prion protein pathology, along with investiga-
tions on Aβ, phospho-tau, α-synuclein and TDP-43 accu-
mulation in the CNS. The findings in this cohort are com-
pared to age-matched UK cases of sCJD and vCJD, and in 
a small group of UK hDM-iCJD cases. Most importantly, 
we have a control cohort of 12 UK hGH recipients who 
did not develop iCJD, but died from complications of the 
underlying medical conditions that caused their hGH defi-
ciency; no similar cohorts have yet been studied in this 
way. The hGH control group allows the potential influence 
of iCJD pathology on CNS Aβ accumulation in hGH recip-
ients to be assessed more fully than hitherto possible. The 
extensive laboratory-based data on these groups of patients 
is matched by detailed clinical data, including the dates and 
duration of hGH treatment in the 35 hGH-iCJD cases and 
the 12 hGH control cases, and the type of hGH prepara-
tions that were used during the period of treatment. Genetic 
data are also available for most cases, including the APOE 
genotype and data on a range of other genes that might 
influence Aβ accumulation in the CNS of these individuals.
Materials and methods
Cases, inclusion criteria and tissue specimens
All cases included in this study were of UK origin and were 
referred to the National CJD Research & Surveillance Unit 
(NCJDRSU) between 1991 and 2016 for neuropathological 
diagnosis and surveillance purposes. Diagnoses were made 
according to internationally accepted criteria for human 
prion diseases [66]. Inclusion criteria for the cases investi-
gated in this study were: a definite diagnosis of hDM-iCJD, 
hGH-iCJD, or a documented history of treatment with UK 
hGH with no clinical or neuropathological evidence of a 
human prion disease (hGH control cases), the availability 
of formalin-fixed CNS tissue taken at post-mortem and 
appropriate consent and ethical approval for retention and 
research use. The study identification number and basic 
patient data for five hDM-iCJD, 35 hGH-iCJD and 12 hGH 
control patients who fulfilled these inclusion criteria are 
detailed in Online Resource Table 1. None of the 35 hGH-
iCJD examined in this study were included in the small 
series of recent UK hGH-iCJD cases reported by Jaunmuk-
tane et al. [29]. The age range at death for the hDM-iCJD 
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(27–47 years), hGH-iCJD (20–46 years) and hGH con-
trol cases (13–45 years) are shown in Fig. 1. Thirty-three 
UK cases of vCJD and 15 sCJD cases of known PRNP 
codon 129 genotype, with age at death ranging from 20 to 
46 years, were included as age-matched controls (Fig. 1). 
All CJD and control tissues were provided by the MRC 
Edinburgh Brain Bank.
Formalin-fixed, formic acid treated, paraffin-embedded 
tissue samples from multiple CNS regions (frontal, pari-
etal, occipital and temporal cortices, hippocampus, amyg-
dala, basal ganglia, thalamus, brain stem, cerebellum and 
spinal cord), including the brain regions recommended in 
the National Institute on Aging-Alzheimer’s Association 
guidelines for the assessment of Alzheimer’s disease, were 
examined whenever possible [26]. In addition, formalin-
fixed non-CNS tissue samples were available in 19 of the 
35 hGH-iCJD and two of the 12 hGH control cases for 
examination. All CNS and non-CNS tissue sections were 
cut at 5 µm for immunohistochemistry and stained for hae-
matoxylin and eosin (H&E). Additionally, sections of the 
frontal, parietal, occipital and temporal cortices were cut at 
8 µm for the Bielschowsky silver stain for neuritic plaques 
following the protocol described in Dawson et al. [10].
Antibodies and immunohistochemical analysis
Sections from all CNS tissues were labelled with two 
monoclonal anti-PrP antibodies recognising different 
epitopes of the prion protein: 12F10 (amino acids 142–
160, Bioquote Ltd, UK) and KG9 (amino acids 140–180, 
TSE Resource Centre, Roslin Institute, UK). CNS tissue 
sections were stained by immunohistochemistry for Aβ 
(6F3D, Dako, UK and 4G8, BioLegend, UK), Aβ 1–40 
(BioLegend, UK), Aβ 1–42 (BioLegend, UK), phospho-
tau (Thermo Scientific, UK), TDP-43 (2BScientific, UK), 
and α-synuclein (AJ Roboscreen GmbH, Germany). CNS 
blocks from selected hGH-iCJD and hGH control cases 
were also labelled with apolipoprotein E (pan-apoE, Bio-
Legend, UK), apoE-4 (BioLegend, UK), GFAP (Dako, 
UK), ubiquitin (Dako, UK) and CD68 (Dako, UK). Non-
CNS tissues were labelled with the anti-PrP (12F10 and 
KG9) and anti-Aβ antibodies (6F3D and 4G8). Immuno-
histochemistry was carried out using the sensitive Novo-
link™ Polymer Detection System (Leica Biosystems, UK). 
Details of all antibodies used, including pretreatment pro-
tocols, dilutions, incubation times are presented in Online 
Resource Table 3. All washes were carried out in Tris-buff-
ered saline (TBS) (50 mM Tris; 150 mM NaCl; pH 7.6) 
with primary antibodies diluted in antibody diluent (Leica 
Biosystems, UK). Staining was visualised with 3,3′-diam-
inobenzidine (DAB).
To investigate co-localisation within the brain, selected 
CNS sections were double immunostained for Aβ and 
either PrP or phospho-tau, CD68 or GFAP. The pretreat-
ment protocol required for the 12F10 anti-PrP/6F3D 
anti-Aβ antibody, PGM1 anti-CD68/6F3D anti-Aβ anti-
body, AT8 anti-tau/6F3D anti-Aβ antibody or GFAP anti-
GFAP/6F3D anti-Aβ antibody was performed as detailed in 
Online Resource Table 3. Immunolabelling for PrP, CD68, 
phospho-tau and GFAP was performed first. Labelling of 
PrP, CD68 and phospho-tau was carried out in combination 
with the Vectastain Elite ABC HRP (Peroxidase, Mouse 
IgG) Kit (Vector Laboratories, UK; Product PK-6102). 
Labelling for GFAP was performed in combination with 
the Vectastain Elite ABC HRP (Peroxidase, Rabbit IgG) 
Kit (Vector Laboratories, UK; Product PK-6101). Incu-
bations in the primary antibody; 12F10 (1/800), PGM1 
(1/50), AT8 (1/100) and GFAP (1/800) were carried for 
1 h and staining visualised with 3,3′-diaminobenzidine 
(DAB). Staining was continued for Aβ protein with sec-
tions blocked in normal rabbit serum for 20 min before 
incubating in the primary antibody 6F3D (1/250) overnight 
at room temperature. Sections were incubated in a biotin-
SP-conjugated affinity pure rabbit anti-mouse IgG antibody 
(Jackson Immunoresearch Laboratories Inc, USA; Product 
315-065-003) at a dilution of 1/400 in TBS for 1 h before 
a final incubation in Vectastain ABC alkaline phosphatase 
standard (Vector Laboratories, UK; Product AK-5000) for 
30 min. Staining was visualised with Vector red alkaline 
phosphatase substrate kit (Vector Laboratories, UK, cata-
logue PK-SK-5100).
Assessment of CNS tissues for prion‑related pathology
Tissue sections were analysed independently by two expe-
rienced assessors (DLR and JWI). H&E sections from all 
Fig. 1  Age distributions of hGH-iCJD and control cases. The 
sCJD and vCJD control patients were chosen to be as close as pos-
sible in range to the hGH-iCJD cases. Cases of sCJD under the age 
of 50 years are rare; the sCJD control cases are clustered in the 
40–50 years age range with higher mean age values. In contrast, cases 
of vCJD over the age of 40 years are rare; the upper age limit for the 
vCJD cases is 41 years. Vertical bars represent the mean with stand-
ard deviation values
 Acta Neuropathol
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CNS regions were assessed for the distribution, severity 
and nature of spongiform change, neuronal loss, gliosis and 
amyloid plaque formation and scored in a semiquantitative 
manner [46] using 4 scores (0—absent, 1—mild, 2—mod-
erate, 3—severe). All CNS sections from the hGH-iCJD 
cases stained with the anti-PrP antibodies were examined 
to determine the distribution, severity and nature of the 
abnormal PrP accumulation (granular, perineuronal/peri-
cellular, plaque-like, plaques, amorphous deposits, perivas-
cular, vascular). The findings were assessed in conjunction 
with those from the examination of the H&E sections to 
allow subclassification by histotyping [46, 47] to determine 
whether the patterns of neuropathology observed in the 
hGH-iCJD cases resembled those occurring in recognised 
sCJD subtypes or not.
Assessment of Aβ and phospho‑tau pathology
An “ABC” score for the level of Alzheimer’s disease neuro-
pathology was calculated for each hGH-iCJD, hGH control, 
hDM-iCJD, vCJD control and sCJD control case accord-
ing to Hyman et al. [26]. This score was derived from the 
classification of the Aβ phase on sections stained using the 
Aβ immunohistochemistry (“A” score: Thal phase for Aβ 
deposits) [65], the Braak and Braak neurofibrillary change 
stage using immunohistochemistry for phospho-tau (“B” 
score: Braak & Braak stage for neurofibrillary changes) 
[5, 6] and the neuritic plaque score on Bielschowsky sil-
ver-stained sections by the method of the Consortium to 
Establish a Registry for Alzheimer’s Disease (CERAD) 
(“C” score: the CERAD score for neuritic plaques) [43]. 
All cases were also assessed for cerebral amyloid angiopa-
thy (CAA) in vessels in the leptomeninges, the brain paren-
chyma and brain capillaries. CAA was scored according to 
the criteria of Love et al. [39]. In addition, cases with CAA 
were also stained with the anti-Aβ 1–40 antibody and the 
anti-Aβ 1–42 antibody and the distribution of immunore-
activity for each antibody in the CAA blood vessels was 
recorded.
Immunohistochemistry for apoE and apoE‑4
Sections of the CNS from cases of hGH-iCJD and hGH 
controls for which no frozen tissue was available for 
APOE genotype analysis were stained with antibodies to 
apoE and apoE-4 (Online Resource Table 2). As in a pre-
vious publication using apoE immunohistochemistry [60], 
the specificity of immunolabelling with these antibodies 
was confirmed on cases of Alzheimer’s disease of known 
APOE genotypes (Ɛ3/3, Ɛ3/4 and Ɛ4/4) as positive controls 
for apoE and apoE-4 expression, with appropriate nega-
tive controls. The hGH-iCJD cases and hGH control cases 
with CNS Aβ accumulation that showed selective labelling 
with both anti-apoE-4 antibodies were judged to be cases 
with an apoE-4 phenotype and categorised as apoE-4 +ve 
(IHC); cases with CNS Aβ accumulation but no evidence 
of apoE-4 labelling were categorised as apoE-4-ve (IHC).
Paraffin‑embedded tissue blot
Paraffin-embedded tissue (PET) blotting was performed 
on all formalin-fixed, non-CNS tissues from hGH-iCJD 
and hGH control cases as previously described [58]. PET 
blotting was performed using two monoclonal anti-PrP 
antibodies recognising different epitopes of the prion pro-
tein; 3F4 (amino acids 109–112, Cambridge Bioscience, 
UK) and 12F10 in combination with the Vectastain ABC-
AmP kit (Vector Laboratories, Peterborough, UK; Prod-
uct AK-6400). Briefly, 5-µm tissue sections were mounted 
onto 0.45-µm nitrocellulose membrane and incubated over-
night at 55 °C. Nitrocellulose-mounted tissue sections were 
deparaffinised before an overnight digestion in 25 µg/ml 
proteinase K (Roche Diagnostics; Product 03115 836 001). 
Membranes were washed in TBST (10 mM Tris HCl pH 
7.8, 100 mM NaCl, 0.05% Tween 20) before treatment with 
3 mol/l guanidine isothiocyanate for 10 min. After a further 
wash tissue sections were blocked with casein and incu-
bated for 2 h in the primary antibodies (12F10, 1/22 000; 
3F4, 1/500) diluted in casein. Immunolabelling was com-
pleted using the Vectastain ABC-AmP kit and staining vis-
ualised using the nitro blue tetrazolium/5-bromo-4-chloro-
3-indolyl phosphate (NBT/BCIP) chromogen system.
APOE genotyping
APOE genotyping was performed by competitive allele-
specific PCR, using KASP™ genotyping assays (LGC 
Genomics, Hoddesdon, UK) for both rs7412 and rs429358. 
Subsequent genotype data was converted into APOE allele 
status [70]. Full methods for the KASP™ genotyping 
platform are available from LGC Genomics (http://www.
lgcgenomics.com/genotyping/kasp-genotyping-reagents/).
Exome sequencing and analysis
As previously described [31], genomic DNA was frag-
mented, exome enriched and sequenced (Nextera Rapid 
Exome Capture 62 Mb or TruSeq rapid 37 Mb kit on a 
HiSeq 2000 with 100 bp paired-end reads). Bioinformatic 
analysis was performed using an in-house pipeline includ-
ing alignment (human reference genome hg19, UCSC) 
using Burrows-Wheeler Aligner (BWA) [38]. Variant call-
ing was performed using FreeBayes [18]. Subsequent anal-
ysis was restricted to on-target homozygous, heterozygous, 
and compound heterozygous variants with a minimum read 
depth of 10, and base quality score of 20. Further analysis 
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selected variants in 5′ untranslated region (UTR), 3′ UTR 
or exonic regions within genes of interest that may influ-
ence the aggregation of Aβ in the CNS (APP, C9ORF72, 
CHMP2B, CSFIR, FUS, GRN, ITM2B, MAPT, NOTCH3, 
PSEN1, PSEN2, SERPINI1, SQSTM1, TARDBP, TREM2, 
TYROBP, VCP) and with a minor allele frequency <5% in 
the 1000 Genome Project Database [1] of European/Ameri-
can cases from the NHLBI ESP exomes database [45] 
and the ExAC server [14], using Qiagen Ingenuity Variant 
Analysis software (Qiagen, Hilden, Germany).
Western blotting with sodium phosphotungstic acid 
precipitation
Western blot analysis of protease-resistant prion protein 
(PrPres) in non-CNS hGH-iCJD tissues was performed 
using the highly sensitive sodium phosphotungstic acid 
(NaPTA) precipitation method as previously described [20, 
51, 69]. Briefly, 10% w/v extracts were made by homog-
enising tissues in an appropriate volume of 2% sarkosyl/
phosphate-buffered saline (PBS), pH 7.4, using the Fast-
Prep instrument (Qbiogene, Cambridge, UK). The samples 
were then cleared by centrifugation at 5200g for 5 min at 
4 °C. Cleared spleen tissue homogenate (5%) from a non-
CJD patient was used as a negative control. In addition, 
iCJD or sCJD brain tissue homogenate (10%, 10 µl cor-
responding to 100 µg brain) was diluted and mixed into 
1 ml of 5% cleared non-CJD spleen tissue homogenate, for 
use as a positive control. Samples (0.5 ml) of the cleared 
lysates were diluted with a further 0.5 ml of 2% sarkosyl/
PBS and incubated for 10 min at 37 °C. Benzonase (Sigma, 
UK) and MgCl2 were added at final concentrations of 50 U/
ml and 1 mmol/l, respectively, and incubation at 37 °C was 
continued for a further 30 min. 81 μl of a stock solution 
of 4% w/v NaPTA and 170 mmol/l MgCl2, pH 7.4, were 
added (final concentration of NaPTA, 0.3% w/v), and pre-
cipitation developed for 30 min at 37 °C. Samples were 
centrifuged at 20,800g for 30 min at 37 °C. The resultant 
supernatant was discarded and the pellets resuspended in 
20 μl of 0.1% w/v sarkosyl in PBS, pH 7.4, and digested 
with 50 μg/ml proteinase K for 30 min. Digestion was ter-
minated by the addition of 1 mmol/l PefaBloc SC (Roche, 
UK). Electrophoresis was performed using the NuPAGE 
Novex gel system (Invitrogen). Before electrophoresis, 
NuPAGE LDS sample buffer was added to each of the sam-
ples to a final concentration of 1×. Samples were boiled 
for 10 min and separated on 10% Bis–Tris NuPAGE gels. 
The separated proteins were then transferred onto PVDF 
membrane (Bio-Rad, UK). For immunodetection, the anti-
PrP monoclonal antibody 3F4 (Dako, UK) was used at a 
final concentration of 50 ng/ml IgG for 1 h. Horseradish 
peroxidase-conjugated anti-mouse IgG F(ab′)2 fragment 
(Sigma-Aldrich, Dorset, UK)) was used at a dilution of 1 in 
40,000 for 1 h. The detection reagent used was SuperSignal 
West Femto Maximum Sensitivity Substrate (Thermofisher 
Scientific).
Statistical analysis
Advice on appropriate methods for statistical analyses was 
kindly provided by Dr Anna Molesworth, Senior Epidemi-
ologist, NCJDRSU, University of Edinburgh and Catriona 
Graham, Lead Statistician, Edinburgh Clinical Research 
Facility, University of Edinburgh.
Excel (Microsoft, Reading, UK) and Prism 7.00 (Graph-
Pad Software, Inc, La Jolla, USA, on license) were used 
for data storage and processing for statistical analysis of 
the data. The threshold used for statistical significance was 
p < 0.05. All graphs were generated using GraphPad Prism 
7.00 (GraphPad Software, Inc, La Jolla, USA, on license).
Results
Clinical features
Thirty-five autopsy cases of hGH-iCJD with formalin-
fixed CNS tissue were available for neuropathological 
analysis. The study identification numbers and clinical 
data including; sex, age at death, age at disease onset, 
duration of illness, incubation period, PRNP codon 129 
genotype, duration of hGH treatment, the mid-point of 
treatment to death and the original diagnosis for all 35 
patients are shown in Online Resource Tables 1 and 2. In 
addition, clinical summaries of 12 hGH recipients with no 
clinical or neuropathological evidence of a human prion 
disease (hGH control cases) were available for examina-
tion and are detailed in Online Resource Tables 1 and 2. A 
full biochemical characterisation and prion protein genetic 
analysis of 21 of the 35 hGH-iCJD (hGH-iCJD1–hGH-
iCJD21) patients in which frozen autopsy tissue was avail-
able has been published separately, along with some pre-
liminary neuropathological findings [57]. The age range at 
death was similar for the hGH-iCJD (20–46 years, mean 
31.2 years ± SD 6.7 years) and hGH control (13–45 years, 
mean 29.5 ± 9.8 years) cases (Fig. 1). PRNP codon 129 
genotype was available in 30 of these 35 hGH-iCJD cases 
and confirmed our earlier findings that the MV (15 cases) 
and VV (11 cases) codon 129 genotypes dominate in UK 
hGH-iCJD cases and that these tended to occur earlier in 
the hGH-iCJD epidemic than the MM PRNP codon 129 
cases (4 cases) [57]. This is in contrast to sCJD in the UK 
where the MM PRNP codon 129 genotype is the most fre-
quently occurring group.
All hGH patients examined had received treatment with 
hGH during the period 1969–1985 with the duration of 
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hGH treatment varying from 2–11.2 years for the hGH-
iCJD cases to 1–12.3 years for the hGH control cases 
(Online Resource Table 2). One form of UK pituitary-
derived hGH, the modified Wilhelmi preparation, had 
been administered to all hGH recipients who had devel-
oped iCJD, albeit in varying quantities and over different 
time periods [59, 64]. All 35 hGH-iCJD patients in this 
study had received hGH produced by the modified Wil-
helmi method for treatment periods of between 6 months 
and 8.2 years. In contrast, only eight of the 12 hGH-con-
trol patients received the modified Wilhelmi preparation 
for treatment periods ranging from 4 months to 6.6 years. 
In agreement with our earlier data, statistically significant 
associations were found between the PRNP codon 129 
genotype and disease incubation periods and duration of 
illness in the hGH-iCJD patients [57]. The four codon 129 
MM hGH-iCJD patients had the longest incubation periods 
in comparison to the MV and the VV patients. In contrast, 
codon 129 MV patients have a significantly longer dura-
tion of illness in comparison to the MM and VV patients 
(Fig. 2). Clinical data from five hDM-iCJD autopsy cases 
with formalin-fixed CNS tissue available for neuropatho-
logical analysis are also provided in Online Resource 
Table 1.
Neuropathological phenotype in hGH‑iCJD 
and hDM‑iCJD
The neuropathological features were reviewed in all 35 
hGH-iCJD cases. The distribution, severity and nature of 
the spongiform change, gliosis, amyloid plaque formation 
and the accumulation of disease-associated prion protein 
on immunohistochemistry were recorded in all cases (fixed 
tissue from case hGH-iCJD1 was not available for PrP 
immunohistochemical analysis). A widespread spongiform 
encephalopathy was present in all cases, accompanied by 
variable neuronal loss and gliosis, with amyloid plaques in 
the cerebellum identified in 16 cases. In general, the distri-
bution and nature of the pathological features in the CNS 
in the hGH-iCJD cases showed close similarities to those 
in sCJD cases with the corresponding PRNP codon 129 
genotype, allowing a histotype to be assigned to each case. 
The histotype assigned to each hGH-iCJD case is detailed 
in Online Resource Table 1.
Three major histotypes were identified in relation to the 
established classification of subtypes of sCJD [47]. All 11 
codon 129 VV cases showed a pattern closely resembling 
that of the sCJD VV2 histotype characterised by micro-
vacuolation, often in a linear distribution in layer 5 of the 
cerebral cortex with severe spongiform change in the basal 
ganglia, the CA1 region of the hippocampus and the subic-
ulum. Severe neuronal loss and gliosis was apparent in the 
cerebellar cortex, often resulting in cerebellar cortical atro-
phy (Fig. 3a). PrP immunohistochemistry shows granular 
and perineuronal deposits in the cerebral cortex in layer 5, 
with decoration of apical ascending dendrites. Plaque-like 
deposits occurred throughout the brain, but no true amyloid 
plaques were detected (Fig. 3e, i). Three additional cases 
(hGH-iCJD29, 30 and 32) for which no PRNP codon 129 
genotype data were available had neuropathological fea-
tures corresponding to the sCJD VV2 histotype.
Fourteen of the 15 codon 129 MV patients showed a 
pathology closely associated with the sCJD MV2K histo-
type with predominantly microvacuolation in the cerebral 
cortex, hippocampus, basal ganglia and thalamus and cer-
ebellar cortex. The presence of occasional areas of conflu-
ent spongiform change in the cerebral cortex in four cases 
allowed further subclassification as MV2K + 2C. Kuru-
type amyloid plaques were present in the cerebellum in 
all 14 cases, and occasionally in the cerebral cortex. Peri-
neuronal, kuru-type plaques and plaque-like PrP deposits 
were observed in the cerebellum, basal ganglia, thalamus, 
Fig. 2  Relationship of PRNP codon 129 polymorphisms to hGH-
iCJD incubation period and disease duration. a Differences in the 
incubation periods for hGH-iCJD in relation to PRNP codon 129 gen-
otype. b Differences in the hGH-iCJD disease duration in relation to 
PRNP codon 129 genotype. Statistical analyses were performed using 
one-way ANOVA followed by Tukey’s multiple comparison test; hor-
izontal bars represent mean with standard deviation values
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hippocampus and occasionally in the cerebral cortex 
(Fig. 3b, f, j). The remaining codon 129 MV case had a 
pathology more in keeping with the sCJD MV2C histotype, 
with a predominantly confluent spongiform change in the 
cerebral cortex and a perivacuolar pattern of PrP deposi-
tion. Kuru-type amyloid plaques were not observed in this 
case. One additional case for which no PRNP codon 129 
genotype could be determined (hGH-iCJD33), had neuro-
pathological features corresponding to the sCJD MV2K 
histotype.
Two of the four codon 129 MM cases showed fea-
tures associated with the sCJD MM1/MV1 subtype, with 
a widespread spongiform encephalopathy of microvacu-
olar type, most severe in the frontal and occipital cortex. 
Patchy spongiform change was observed in the cerebellar 
cortex, with no amyloid plaques. PrP deposition showed a 
widespread granular pattern (Fig. 3c, g, k). One additional 
case (hGH-iCJD25) for which no PRNP codon 129 geno-
type data were available had neuropathological features 
corresponding to the MM1/MV1 histotype. Four of the 
five hDM-iCJD cases showed a neuropathological pheno-
type closely resembling that of sCJD MM1/MV1 histotype, 
while hDM-iCJD4 resembled the sCJD VV2 histotype. 
Kuru-type amyloid plaques were not observed in any hDM-
iCJD cases. No evidence of a spongiform encephalopathy 
or prion protein immunoreactivity was found in any of the 
hGH-control cases.
Atypical neuropathology in hGH‑iCJD
Two PRNP codon 129 MM cases (hGH-iCJD20 and 
hGH-iCJD31) showed neuropathological features that 
did not correspond to those described by Parchi et al. 
[47] in MM codon 129 cases of sCJD. Case hGH-iCJD20 
was reported in detail in our earlier publication [57] and 
showed the presence of kuru plaques and PrP plaque-
like deposits in the cerebellum and cerebral cortex in a 
phenotype more in keeping with that of sCJD MV2K 
subtype (sCJD MV2K + 2C histotype) than the MM1/
MV1 histotype. Case hGH-iCJD31 shared some of the 
atypical features seen in hGH-iCJD20, with predomi-
nantly microvacuolar spongiform change in the cerebral 
cortex, particularly in layers 5–6, hippocampus and basal 
ganglia (Fig. 3d). The thalamus and cerebellum showed 
Fig. 3  Typical neuropathological phenotypes in UK hGH-iCJD. 
PRNP codon 129 VV hGH-iCJD cases show microvacuolation in the 
cerebral cortex (a) with a combination of granular, perineuronal and 
plaque-like accumulations of PrP in the cerebral cortex (e). The cer-
ebellar cortex in VV hGH-iCJD cases shows a predominantly granu-
lar pattern of PrP accumulation (i). PRNP codon 129 MV hGH-iCJD 
were characterised by the presence of kuru plaques in the cerebellar 
and occasionally in the cerebral cortex (b, f, j). PRNP codon 129 
MM hGH-iCJD cases show widespread microvacuolation in the cer-
ebral cortex (c) with a predominantly granular accumulation of PrP in 
the cerebral (g) and cerebellar cortex (k). Case hGH-iCJD31 shows 
atypical neuropathological features in comparison with the codon 129 
MM hGH-iCJD cases. Microvacuolation was observed in the lower 
layers of the cerebral cortex (d) with a combination of granular, per-
ineuronal and plaque-like accumulations of PrP in the cerebral and 
cerebellar cortex (h, l). No kuru-type amyloid plaques were present 
in any brain region. These features show some similarities to the VV2 
histotype in sCJD. Sections a, c, e, and g, are stained with H&E and 
sections b, d, f, and h are stained with the KG9 antibody. The bar in 
a represents 25 µm for a, c–l; and 15 µm for b
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less spongiform change, but no kuru-type plaques were 
identified in the cerebellum. PrP immunohistochemis-
try showed a combination of granular, perineuronal and 
plaque-like PrP deposits in a widespread distribution in 
the CNS. An occasional PrP plaque-like deposit was pre-
sent in the parietal cortex, with intense labelling on PrP 
immunohistochemistry (Fig. 3h, l). This phenotype was 
distinct from both the MM/MV1-like histotype and the 
MV2-like histotype in hGH-iCJD, and from MM1 and 
MV2 histotype in sCJD. However, there are some similar-
ities to the VV2 phenotype in both sCJD and hGH-iCJD.
Co‑pathology and Aβ accumulation in hGH‑iCJD 
and hGH controls
Of the 35 hGH-iCJD cases, 33 had sufficient paraffin-
embedded tissue for further pathological analysis by immu-
nohistochemistry. Aβ was detected as CAA and/or CNS 
parenchymal deposits in 18 of the 33 hGH-iCJD cases. Of 
these 18 Aβ-positive cases, six had CAA only, four had 
parenchymal deposits without CAA and eight cases had 
both CAA and parenchymal deposits (Fig. 4). Parenchymal 
Aβ deposits occurred in the form of diffuse (immature) and 
cored plaques, neuritic plaques and subpial deposits in the 
cerebral cortex in an unpredictable and varied distribution, 
either singly or in clusters, in one or more cortical regions 
(Fig. 5a–c). The occurrence of Aβ plaque clusters has also 
been reported in hDM-iCJD cases, but we found relatively 
more diffuse Aβ plaques than in the hDM-iCJD cases, 
which contained predominantly cored Aβ plaques [35, 36]. 
In the hGH-iCJD cases who had undergone neurosurgery 
for tumour resection (Online Resource Table 2), we did not 
observe the accentuation of Aβ accumulation around the 
operation sites that was reported in hDM-iCJD cases [35, 
36]. There was no relationship between the location of the 
Aβ parenchymal deposits and either the vascular bound-
ary zone areas in the brain or the topography of the cer-
ebral gyri (including the depth of the sulci). Furthermore, 
we found no relationship between the morphology of the 
parenchymal Aβ deposits and either the patterns of prion 
protein accumulation in the brain or the severity or the 
nature of the spongiform change. No evidence of co-local-
isation of Aβ deposits with the kuru-type plaques or focal 
plaque-like deposits in the hGH-iCJD cases was noted. 
However, it was not possible to establish with certainty 
that there was clear separation of the Aβ deposits from the 
widespread granular PrP positivity in affected cortical grey 
matter in hGH-iCJD cases. All 12 hGH-iCJD cases with 
parenchymal Aβ deposits contained diffuse plaques, with 
cored plaques found in 6/12 cases and neuritic plaques 
identified with the Bielschowsky silver stain in 5/12 cases 
(Fig. 5c). The plaque frequency varied from occasional 
diffuse grey mater plaques to more numerous diffuse and 
neuritic plaques (up to CERAD score 2). Immunohisto-
chemistry for phospho-tau showed only small numbers of 
fine neuritic processes around the Bielschowsky-positive 
neuritic plaques. Patchy diffuse subpial Aβ deposits were 
also present in five cases, but other forms of diffuse Aβ 
(such as lake-like or fleecy deposits) were absent (Fig. 5d). 
No Aβ deposits were identified in the entorhinal cortex, 
hippocampus, basal ganglia, thalamus, brain stem, cerebel-
lum, spinal cord or white matter. 
CAA in 14 hGH-iCJD cases varied from occasional 
focal Aβ deposits in meningeal vessel walls to more 
extensive circumferential deposition in meningeal and 
intraparenchymal vessels, with variable perivascular Aβ 
accumulation (Fig. 5e–h). None of the hGH-iCJD cases 
showed vasculopathy related to CAA. Case hGH-iCJD18 
displayed sparse capillary CAA in addition to parenchymal 
and meningeal CAA. CAA was present most often in the 
Fig. 4  Frequency of Aβ accumulation in hGH-iCJD and control 
cases. There is a significant difference in the percentage of cases with 
CNS Aβ deposition in the two groups treated with hGH (51%) com-
pared to the three groups not treated with hGH (6%); p < 0.001 (Fish-
er’s exact test). Comparison of the hGH-iCJD, hGH control and non 
hGH-treated groups confirms the association between CNS Aβ accu-
mulation and hGH treatment; p < 0.001 (Chi-squared test)
Acta Neuropathol 
1 3
occipital meningeal vessels and occipital cortex, but occa-
sional cases had isolated CAA in the parietal or frontal cor-
tex. A single case also had CAA in the cerebellar menin-
geal vessels, with no cerebellar parenchymal involvement 
(Fig. 5g). None of the CAA-affected vessels were labelled 
with the anti-PrP antibodies.
Similar patterns of CNS Aβ accumulation were identi-
fied in five of the 12 hGH control cases examined. Three 
of these five Aβ positive cases contained parenchymal Aβ 
deposits only with a single case containing meningeal and 
intraparenchymal CAA, but no parenchymal deposits or 
capillary CAA (Figs. 4, 5i, j). The remaining case (hGH-
control11) had extensive meningeal, intraparenchymal and 
capillary CAA widespread diffuse and neuritic cerebral 
cortical plaques with scanty neurites (up to CERAD score 
2), and patchy subpial Aβ deposits (Fig. 5k, l). Dyshoric 
CAA vessels were also present in this case and occasional 
Aβ-laden vessels exhibited splitting of the vessel wall 
(Fig. 5m–p). Immunohistochemistry for Aβ 1–40 and Aβ 
1–42 showed similar results for hGH-iCJD and hGH con-
trol cases with preferential labelling of CAA and plaque 
cores with Aβ 1–40, while the Aβ 1–42 antibody showed 
Fig. 5  Aβ accumulation in the CNS in hGH-iCJD and hGH control 
patients. Aβ immunohistochemistry (6F/3D antibody) in hGH-iCJD 
(a–h) and hGH control (i–p) cases. Diffuse plaques were a feature 
of all hGH-iCJD cases in which CNS Aβ deposition was observed 
(a). Cored plaques were less frequently observed in hGH-iCJD cases 
(b) with neuritic plaques demonstrated with the Bielschowsky silver 
stain (c). Patchy diffuse subpial deposits of Aβ were also a feature of 
hGH-iCJD cases (d). Patchy deposition of Aβ in the wall of a menin-
geal vessel with a more extensive Aβ deposition in occipital vessels 
in the meninges and adjacent cortex in hGH-iCJD (e, f). Patchy Aβ 
deposition was observed in the wall of meningeal vessels overlying 
the cerebellar cortex in a single hGH-iCJD case (g). Circumferential 
deposition in a cortical arteriole with extensive perivascular Aβ form-
ing a cored plaque-like structure (h). Diffuse Aβ deposits and plaques 
were also found in the cerebral cortex in hGH control cases (i). CAA 
with patchy meningeal deposits and circumferential deposition were 
observed in the superficial cortical vessels in hGH control cases (j). 
hGH control11 showed extensive CAA in the meninges and cortex 
with diffuse and perivascular Aβ deposits and multiple cored plaques 
and smaller diffuse Aβ deposits (k, l). This case also showed severe 
capillary CAA with marked thickening of vessel walls, the presence 
of dyshoric cortical vessel and vasculopathy shown with the splitting 
of an intracortical arteriole wall (m–o). Meningeal and intracortical 
CAA with diffuse subpial deposits, perivascular deposits and diffuse 
and cored Aβ plaques in hGH control case11 (p). The bar in a repre-
sents 50 µm for a, b, d–e, g, i, l, p; 20 µm for h, m–o; 25 µm for c; 
and 100 µm for f, j, k
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more labelling of diffuse Aβ deposits in the subpial region, 
diffuse plaques and the diffuse corona around some cored 
plaques (Fig. 6a, b). Sparse phospho-tau positive neurites 
were identified around cored Aβ plaques and around some 
large Aβ deposits surrounding intraparenchymal blood ves-
sels in the hGH control cases (Fig. 6c, d). Phospho-tau-
positive neurites were also sparse in hGH-iCJD cases, but 
more neurites were identified following labelling with the 
ubiquitin antibody (Fig. 6e). Reactive astrocytes and micro-
glia were identified around and within cored Aβ plaques in 
both hGH-iCJD and hGH control cases (Fig. 6f–h).
In contrast to hGH-iCJD cases, the diffuse Aβ plaques 
in the occipital and parietal cortex of two vCJD cases 
(vCJD22 and vCJD32) appeared to co-localise with 
the PrP amyloid in some florid plaques. However, dou-
ble IHC with antibodies to Aβ and PrP showed separa-
tion of some diffuse Aβ deposits from the florid plaques 
and other forms of focal PrP accumulation in the corti-
cal grey matter in vCJD (Fig. 6i, j). No cored or neu-
ritic Aβ plaques were identified and no meningeal or 
parenchymal CAA was present. A single sCJD control 
case (sCJD14) showed focal Aβ deposits in the walls 
of occasional small- to medium-sized meningeal blood 
vessels over the occipital and temporal lobes and in the 
superficial occipital cortex, with very few vessels exhib-
iting circumferential deposition (Fig. 6k). No PrP label-
ling in these vessels was identified.
The ABC and CAA scores for the hGH-iCJD, hGH 
control, vCJD and sCJD cases are summarised in 
Table 1.
No Aβ labelling was identified in either the CNS 
parenchyma or blood vessels in three of the hDM cases 
with sufficient paraffin tissue available further patholog-
ical analysis by immunohistochemistry.
Phospho‑tau, α‑synuclein and TDP‑43 pathology
Phospho-tau immunolabelling was present in all CJD cases 
analysed, irrespective of aetiology in the form of small 
neuritic dots in the neuropil as previously described [36]. 
Labelling of fine neuritic processes was noted around kuru 
plaques in sCJD controls and florid plaques in vCJD con-
trols (Online Resource Fig. 1). Small numbers of AT8-pos-
itive pretangles labelled in the superior frontal cortex in a 
Fig. 6  Aβ pathology in hGH recipients, sCJD and vCJD. Immuno-
histochemistry with Aβ 1–40 antibody shows intense labelling of Aβ 
within cerebral vessels and plaque cores (a). A serial section labelled 
with the Aβ 1–42 antibody showing intense labelling of a large dif-
fuse Aβ deposit (b). Phospho-tau positivity (brown) in neurites 
around Aβ (red) in a cored plaque and dyshoric vessel with CAA in 
hGH control11 (c, d). The ubiquitin antibody labels extensive neur-
ites around a cored Aβ plaque in hGH-iCJD (e). Reactive astrocytes 
around a cored Aβ plaque revealed on double labelling for Aβ (6F/3D 
antibody-red) and GFAP (GFAP antibody-brown) in hHG-iCJD (f). 
Astrocytes (brown) surround a cored Aβ plaque (red) (g) and micro-
glial cells (brown) are present within a cored Aβ plaque (red) in hGH 
control10 (h). Diffuse Aβ deposits in the parietal cortex in vCJD27 
(i). The diffuse cortical Aβ deposits in vCJD 37 (red) are shown not 
to co-localise with the abundant PrP deposits (brown) (j). Patchy 
localised meningeal CAA in the occipital region in sCJD14 (k). 
APOE-4 positivity in diffuse Aβ deposits in hGH control6 (l). The 
bar in a represents 100 µm for a–b; 20 µm for f, h; 25 µm for c–e, g, 
j, l; and 50 µm for i, k
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single hGH-iCJD (hGH-iCJD31) patient with idiopathic 
hGH deficiency. No Aβ or other adjacent pathology was 
observed and no phospho-tau positivity was identified in 
any other brain region. Small numbers of AT8-positive pre-
tangles and occasional neurofibrillary tangles labelled in 
the gliotic region in the inferior right temporal cortex in a 
single hGH control patient who had undergone resection 
of an ependymoma (Online Resource Fig. 1). This local-
ised abnormality was not associated with Aβ deposition. No 
α-synuclein or TDP-43 labelling was found in any of the 
cases examined.
Correlations with Aβ pathology in hGH‑treated 
patients
The frequency of Aβ-positive cases in both the hGH-
iCJD and hGH control groups are significantly higher 
than in the sCJD and vCJD age-matched controls 
(Fig. 3). No predisposing risk factors for Aβ deposition 
was identified in the clinical histories available for the 
hGH-treated patients. Analysis of the age range at death 
found no statistical difference when comparing the 18 
Aβ-positive hGH-iCJD (20–45 years) cases with the 15 
Aβ-negative hGH-iCJD (20–46 years) cases. However, 
statistically significant differences were found when 
comparing the five Aβ-positive (30–45 years) and seven 
Aβ-negative (13–35 years) hGH control cases (Fig. 7). 
No significant difference was observed in the date 
of first treatment or duration of hGH treatment when 
comparing the Aβ-positive hGH-iCJD and Aβ-negative 
hGH-iCJD cases, but there were non-significant differ-
ences suggesting that the Aβ-positive hGH control were 
treated earlier and for longer than the Aβ-negative hGH 
control cases (Fig. 8). No significant differences were 
Table 1  ABC scores for 
Alzheimer pathology and CAA 
scores for Aβ-positive hGH-
iCJD, hGH control, sCJD and 
vCJD cases
a Cases with diffuse Aβ plaques in the anterior cingulate gyrus in addition to the neocortex, but the full 
Thal phase 2 distribution of Aβ deposits was absent, e.g. in the entorhinal cortex and hippocampus. These 
were therefore recorded as Thal phase 1* as recently reported in hDM-iCJD cases [36]
Study ID ABC score 
(Hyman 
et al. [26])
Hybrid protocol (from Love et al. [39])
A B C Parenchymal CAA Meningeal CAA Capillary CAA Vasculopathy
hGH-iCJD 4 1 0 0 0 0 0 0
hGH-iCJD 5 0 0 0 0 1 0 0
hGH-iCJD 6 0 0 0 1 2 0 0
hGH-iCJD 8 0 0 0 2 2 0 0
hGH-iCJD 9 0 0 0 1 2 0 0
hGH-iCJD 10 1 0 1 2 2 0 0
hGH-iCJD 12 1 0 0 0 0 0 0
hGH-iCJD 15 1 0 0 2 2 0 0
hGH-iCJD 16 1 0 2 1 2 0 0
hGH-iCJD 18 1a 0 2 2 2 1 0
hGH-iCJD 19 1 0 0 2 2 0 0
hGH-iCJD 26 0 0 0 0 1 0 0
hGH-iCJD 29 0 0 0 2 2 0 0
hGH-iCJD 31 1 0 1 1 2 0 0
hGH-iCJD 32 1 0 1 2 3 0 0
hGH-iCJD 33 1 0 0 2 2 0 0
hGH-iCJD 34 1 0 0 0 0 0 0
hGH-iCJD 35 1a 0 0 0 0 0 0
hGH-control6 1a 0 0 0 0 0 0
hGH-control7 1 0 0 0 0 0 0
hGH-control9 0 0 0 2 2 0 0
hGH-control10 1 0 0 0 0 0 0
hGH-control11 1a 0 2 3 3 1 1
sCJD14 0 0 0 1 2 0 0
vCJD22 1 0 0 0 0 0 0
vCJD32 0 0 0 0 0 0 0
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found in either disease incubation period or duration of 
illness in relation to Aβ accumulation in the hGH-iCJD 
patients (Online Resource Fig. 2). The four hGH recipi-
ents who did not receive hGH produced by the modified 
Wilhelmi method had no evidence of Aβ accumulation 
in the CNS and did not develop iCJD (Online resource 
Table 2).
APOE genotype and apoE‑4 phenotype analysis
APOE genotype data were available for 22/33 hGH-iCJD 
cases and 2/12 hGH control cases analysed for Aβ (Online 
Resource Table 2; Table 2). No APOE-ɛ4 homozygous geno-
types were found and a mixture of APOE-ɛ2/3, APOE-ɛ3/3 
Fig. 7  CNS accumulation and age at death in hGH-iCJD and hGH 
control cases. Comparisons of the age at death for a hGH-iCJD and 
b hGH-control patients in relation to accumulation of Aβ. No signifi-
cant difference in the age at death was found between the Aβ-positive 
and Aβ-negative hGH-iCJD cases. However, a significant difference 
was found between the Aβ-positive and Aβ-negative hGH control 
cases, with the Aβ-positive cases showing a higher age at death. Sta-
tistical analysis was performed using an unpaired t test
Fig. 8  Treatment times with hGH-iCJD and hGH control patients. 
a Shows the year of first treatment for hGH-iCJD and hGH-control 
patients in relation to accumulation of Aβ and b shows duration of 
treatment for hGH-iCJD and hGH-control patients in relation to CNS 
Aβ accumulation. Differences were found in both the year of first 
hGH treatment and duration of treatment in the hGH control cases 
with and without CNS Aβ accumulation, but these did not reach levels 
of statistical significance. Statistical analysis was performed using an 
unpaired t test
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and APOE-ɛ3/4 genotypes was present in the hGH-iCJD 
cases. Immunohistochemistry for apoE-4 in five Aβ-positive 
hGH-iCJD cases found no positives (Table 2). In the five 
hGH control cases with CNS Aβ accumulation there was a 
single case with the APOE-ɛ3/3 genotype and another with 
the APOE-ɛ3/4 genotype. Immunohistochemistry for apoE-4 
in the three remaining Aβ-positive hGH control cases found 
a single positive case (hGH control 6) (Fig. 6l; Table 2). As 
previously reported [60], only the parenchymal Aβ deposits 
and occasional neurites were labelled with the antibodies to 
apoE-4. Consequently, no information on the APOE geno-
type or apoE-4 phenotype can be obtained on the remain-
ing 6 hGH-iCJD cases and the 7 hGH control cases with no 
CNS Aβ accumulation, due to a lack of frozen tissue sam-
ples and the absence of Aβ pathology. Comparison of APOE 
genotypes and Aβ accumulation found no statistical differ-
ences between the Aβ-positive and Aβ-negative hGH-iCJD 
cases; comparisons between the Aβ-positive and Aβ-negative 
hGH control cases was hampered by a lack of APOE geno-
type data for the Aβ-negative cases (Online Resource Fig. 3). 
The two vCJD cases with diffuse Aβ parenchymal deposits 
included one case with the APOE-ɛ3/4 genotype and one 
case with the APOE-ɛ2/3 genotype.
Exome sequencing
Exome sequence analysis data for the hGH-iCJD cases, 
hGH-controls and sCJD cases with Aβ accumulation and 
with frozen tissue available found no coding, non-coding 
or 3′ or 5′ untranslated variants in genes that were likely to 
be associated with Aβ accumulation in the CNS. However, 
one of the vCJD cases (vCJD27) with diffuse Aβ deposits 
in the brain had the PSEN1 p.E318G variant that increases 
the risk of AD in APOE-ɛ4 carriers [2] and a −48 C/T pol-
ymorphism in the PSEN1 promoter that is a genotype asso-
ciated with an increased risk of AD and an increased Aβ 
load in the brain [37]. Neither can be considered as highly 
penetrant monogenic alleles causing disease. No other vari-
ants were detected in the vCJD cases.
hGH‑iCJD and hGH control non‑CNS tissues
Twenty-one different non-CNS tissues from 19 hGH-iCJD 
and two hGH controls were available for analysis. There 
was considerable variability in the availability of fixed 
and frozen tissue for each individual case. Details of the 
non-CNS tissues analysed and results of the analysis are 
summarised in Online Resource Table 4. Immunohisto-
chemistry and PET blotting found accumulation of PrP in 
ganglion cells in the trigeminal ganglia and dorsal root gan-
glia (DRG) in all hGH-iCJD cases investigated (Fig. 9a). 
PrP immunopositivity was found in the adrenal gland in 
three hGH-iCJD cases, generally in the chromaffin cells of 
the adrenal medulla (Fig. 9b). In addition, PrP accumula-
tion was observed in the germinal centres in an abdominal 
lymph node in a single hGH-iCJD case (hGH-iCJD15) 
(Fig. 9c). PrP immunoreactivity was also observed in a sin-
gle skeletal muscle sample (hGH-iCJD15), in a linear pat-
tern with a distribution and morphology consistent with that 
of a small nerve, as previously reported (Fig. 9d) [51]. Over 
half of the pituitary glands examined showed PrP immuno-
reactivity predominantly in the neurohypophysis, as previ-
ously described (Fig. 9e, f) [52]. No PrP immunoreactivity 
was observed in the appendix, duodenum, large intestine, 
peripheral nerve, small intestine, spleen, sympathetic chain 
or tonsil in the hGH-iCJD patients or in the hGH control 
tissues by either IHC or PET blot analysis.
Frozen, non-CNS tissue samples were available for anal-
ysis in 11 of the 35 hGH-iCJD cases. Western blot analy-
sis following NaPTA precipitation (NaPTA WB) found 
unequivocal positive reactions in a single DRG and the 
pituitary glands in three cases. Two of the pituitary glands 
were found to have a type 2 PrPres isoform (with a type 2 
and type i + 2 in the corresponding brain samples), while 
the remaining case had a type 1 isoform (Online Resource 
Fig. 4). The brain in the latter case was found to have a 
type 2 PrPres isoform in diagnostic Western blotting. Den-
sitometric analysis indicated that the levels of PrPres in the 
pituitary gland and dorsal root ganglion were around 0.8 
and 0.04%, respectively, in comparison with brain PrPres 
levels in a control hGH-iCJD case. Indeterminate results on 
NaPTA WB (when two of the usual three PrPres bands were 
Table 2  APOE genotypes in hGH-iCJD and hGHcontrol cases
a No information on the APOE genotype or ApoE-4 phenotype can 
be obtained on the remaining 6 hGH-iCJD cases and the 7 hGH con-
trol cases with no CNS Aβ accumulation, due to a lack of frozen tis-
sue samples and the absence of Aβ pathology
b apoE-4 phenotypes were determined on paraffin sections of the 
brains from 5 hGH-iCJD and 3 hGH-control cases with CNS Aβ 
accumulation using immunohistochemistry for the apoE-4 protein
APOE genotype and 
apoE-4 phenotype
hGH-iCJD hGH control
CNS Aβ accumula-
tion
CNS Aβ accumula-
tion
Positive Negativea Positive Negativea
2/2 0 0 0 0
2/3 1 1 0 0
2/4 0 0 0 0
3/3 8 6 1 0
3/4 4 2 1 0
4/4 0 0 0 0
ApoE4 +veb (IHC)a 0 0 1 0
ApoE4 −veb (IHC)a 5 0 2 0
Total 18 9 5 0
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visible), was observed with adrenal gland, bone marrow, 
kidney, heart, lymph node, skeletal muscle and peripheral 
nerve. Skeletal muscle tissue from one case was previously 
found to be positive on NaPTA WB [51]. Repeat NaPTA 
WB analysis of the indeterminate cases was attempted, but 
was restricted in some cases by tissue sample availabil-
ity. None of the repeat NaPTA WB tests altered the clas-
sification of these samples. Immunohistochemistry for Aβ 
showed no labelling in any of the non-CNS tissues in either 
the hGH-iCJD and hGH control cases.
Discussion
This study provides a detailed description of the pathologi-
cal phenotype of the largest series of iCJD cases (35 cases) 
occurring in recipients of hGH in the UK (or indeed any 
country). In doing so, we extend our earlier findings on the 
neuropathological phenotype of 21 (with frozen tissue) of 
these 35 cases, described as part of a thorough molecular 
and genetic analysis of UK hGH-iCJD cases [57]. Perhaps 
more importantly, it also provides a thorough investigation 
of the presence of Aβ, phospho-tau, α-synuclein and TDP-
43 in the hGH-iCJD cases and in non-iCJD hGH recipients 
to establish whether there is evidence of iatrogenic seed-
ing of these disease-associated proteins and whether this is 
independent of CJD transmission [28, 29].
Neuropathological phenotypes of UK hGH‑iCJD 
patients and comparison with sCJD
Iatrogenic CJD in hGH recipients is thought to result 
from contamination of hGH preparations with pri-
ons present in the pituitary gland collected from hGH 
Fig. 9  PrP accumulation in 
non-CNS tissues in hGH-iCJD 
cases. a Immunohistochemistry 
for the prion protein shows 
labelling of the ganglion cells 
in a dorsal root ganglion. b PET 
blot analysis with the 12F10 
anti-PrP antibody shows intense 
labelling (black) of a group 
of chromaffin cells within the 
adrenal medulla, c in germinal 
centres within an abdominal 
lymph node and d in a small 
nerve within skeletal muscle. e 
Immunolabelling for Aβ using 
the 6F/3D antibody shows no 
labelling in the anterior pituitary 
gland, but f the 4G8 anti-Aβ 
antibody shows some diffuse 
fine granular and discrete dot-
like intracellular positivity in 
the endocrine cells. The bar in 
a represents 50 µm for a, b, d; 
25 µm for e, f; and 75 µm for c
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extraction. PrPres has been detected in the pituitary gland 
in sCJD and vCJD patients [52] and, as reported in this 
study, in the pituitary gland in patients with hGH-iCJD. 
The most likely source of prions in hGH preparations 
is sCJD, which is the commonest form of human prion 
disease, occurring most frequently in elderly patients, 
who accounted for the majority of the UK hospital 
autopsies that were the main source of pituitary glands 
collected for hGH extraction. The pathological pheno-
type in sCJD is determined largely by the PRNP codon 
129 genotype of the patient and the PrPres isoform in 
the brain [48]. The results from this study indicate that 
hGH-iCJD is subject to similar influences. The major-
ity of the 35 hGH-iCJD cases showed a similar neuro-
pathological phenotype to the recognised sCJD subtypes 
(Online Resource Table 1). All PRNP codon 129 VV UK 
hGH-iCJD show a pathological phenotype closely similar 
to the sCJD VV2 subtype. Of the 15 PRNP codon 129 
MV hGH-iCJD cases, 14 show a pathological pheno-
type similar to the sCJD MV2K subtype, with the pres-
ence of kuru plaques. In contrast, the PRNP codon 129 
MM subgroup show a divergent phenotype, with two of 
the four MM cases resembling the sCJD MM1 subtype 
in terms of neuropathology. The other two PRNP codon 
MM cases had kuru plaques and plaque-like deposits in 
the CNS. In our earlier publication, we suggest that this 
divergent neuropathological phenotype, combined with 
an intermediate (20 kDa) brain PrPres isoform, may be a 
reflection of incomplete adaptation of the infecting V2 
prion strain in the PRNP codon 129 MM host [57]. This 
pathology has not been described in UK cases of either 
hDM-iCJD or sCJD with a PRNP codon 129 MM geno-
type, but they have been described in cases of hDM-iCJD 
in Japan in PRNP codon 129 MM genotype patients. 
Kobayashi et al. [33] have suggested that the combina-
tion of a PRNP codon 129 genotype and the presence of 
kuru plaques in the cerebellum and cerebral cortex in a 
patient with apparently sporadic CJD should lead to a 
suspicion of an iatrogenic route of infection. In view of 
these results, particular care must be taken in interpret-
ing the neuropathological findings in the five cases in 
which neither PRNP codon 129 genotype nor PrPres iso-
form data are available (Online Resource Table 1). Case 
hGH-iCJD33 had a pathology that resembled the sCJD 
MV2K histotype; however, the possibility that this case 
could have a MM genotype cannot be excluded. Even 
if this were so, over 90% (32/35) of the UK hGH-iCJD 
cases would have neuropathological and biochemical fea-
tures that are indistinguishable from one of the sCJD his-
totypes. With such close similarities in the neuropatho-
logical phenotypes between sCJD and hGH-iCJD cases, a 
detailed clinical history of any potential iatrogenic expo-
sure to CJD prions is essential for diagnosis.
Peripheral pathogenesis in hGH‑iCJD
The peripheral pathogenesis of hGH-iCJD following inocu-
lation of infected hGH preparations by intramuscular and 
subcutaneous injection is not known. Some prion strains 
(including vCJD) replicate in lymphoid tissues before 
invading the CNS. Neuroinvasion may occur via the blood-
borne route, or by slow retrograde spread along autonomic 
nerve to the spinal cord and/or brainstem, then spreading 
to the brain itself [40]. These complex mechanisms partly 
explain the lengthy incubation period in prion diseases 
[32]. The results of this study on a limited range of non-
CNS tissues available give some support for involvement 
of the peripheral nervous system (nerves, dorsal root gan-
glia and trigeminal ganglia) and, for the first time, involve-
ment of lymphoid tissues in a single hGH-iCJD case. It 
may be that hGH-iCJD has some similarities to vCJD in 
terms of its peripheral pathogenesis, but the levels of PrPres 
detected in lymphoid and peripheral nervous system struc-
tures appear lower and more restricted in distribution than 
in vCJD.
CNS Aβ in hGH‑iCJD and hGH control cases 
and associations with Alzheimer’s disease
The possibility of transmission of other neurotoxic pro-
teins that accumulate in the pituitary gland was supported 
by recent evidence of Aβ seeding in the brains of 4/8 hGH 
recipients who died with iCJD [29]. However, all eight 
patients had clinical iCJD, raising the possibility that Aβ 
pathology resulted from cross-seeding, or was in some 
other way contingent on the iatrogenic transmission of 
CJD. Aβ seeding around PrPSc deposits has been reported 
in human prion disease, particularly in genetic prion dis-
eases associated with the formation of PrPSc amyloid 
plaques [9, 27, 44]. In this study, examining a significantly 
larger number of hGH-iCJD cases (including cases from all 
PRNP codon 129 genotypes), CNS Aβ accumulation was 
identified in the cerebral cortex and/or meningeal and intra-
parenchymal blood vessels (including capillaries) in 18/33 
hGH-iCJD. Crucially, our study reports Aβ accumulation in 
5/12 hGH recipient who did not die with iCJD, indicating 
that the Aβ pathology found in hGH recipients is independ-
ent of the development of clinical CJD and the pathological 
changes that underlie it. Aβ pathology was similar in both 
hGH-iCJD and hGH control patients, occurring as paren-
chymal deposits (diffuse subpial deposits, diffuse plaques 
and cored/neuritic plaques) and as CAA, or both parenchy-
mal and CAA. Overall, no major differences are observed 
in the nature or range of severity of the pathology between 
the hGH-iCJD and hGH control groups. The parenchy-
mal Aβ deposits in both groups also had similar astrocytic 
and microglial reactions, which have not been reported in 
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previous studies on CNS Aβ accumulation in cases of iCJD 
[16, 29, 36].
While the parenchymal Aβ deposits in the brains of the 
hGH recipients show similarities to the deposits found in 
Alzheimer’s disease, the distribution of the Aβ pathology 
does not appear to resemble the pattern that is character-
istic of Alzheimer’s disease, but shows a distribution more 
similar to that previously described in hDM-iCJD [36]. 
Other distinctions between the Aβ-positive hGH recipi-
ents and Alzheimer’s disease patients include the notable 
absence of neurofibrillary tangles, a paucity of phospho-
tau-positive neurites around neuritic plaques, the young 
age at death of the hGH recipients and the absence of a 
clinical history of slowly progressive cognitive impair-
ment. All the hGH recipients with CNS Aβ accumula-
tion in our study were under the age of 45 years at death, 
most of whom did not have the APOE-ɛ3/4 genotype or 
apoE-4 phenotype on immunohistochemistry. In a recent 
study of the brains of 154 individuals between the ages of 
30 and 50 years [53], Aβ deposition was not identified in 
any individuals under the age of 40 years, but was present 
in the brains of 13 individuals aged between 40–49 years 
in the form of diffuse plaques throughout the cerebral cor-
tex. None of the cases with Aβ positivity had clinical evi-
dence of dementia or mild cognitive impairment. All indi-
viduals with Aβ positivity carried 1 or 2 APOE ɛ4 alleles; 
however, of the 28 individuals aged 40–50 years with the 
APOE-ɛ3/4 genotype, 10 (36%) had Aβ deposition in the 
brain, but 18 (64%) did not, indicating that the Aβ depo-
sition in the brain before the age of 50 years may occur 
in only around 1/3 of non-demented individuals with the 
APOE-ɛ3/4 genotype [53].
Most of the cases in this study with CAA had the 
APOE-ɛ3/3 genotype, including the two cases with capil-
lary CAA. The hGH-iCJD case with the greatest amount of 
Aβ positivity (hGH-iCJD18) had the APOE-ɛ3/3 genotype 
(combined ABC and CAA score 8), as did the hGH con-
trol case (hGH-control11) with the greatest amount of Aβ 
accumulation in the CNS (combined ABC and CAA score 
11). The single sCJD case with CAA had the APOE-ɛ3/4 
genotype, while the two vCJD cases with diffuse Aβ paren-
chymal deposits comprised one case with the APOE-ɛ3/4 
genotype and one case with the APOE-ɛ2/3 genotype. The 
latter (vCJD 27) was identified on exome sequencing to 
have the PSEN1 p.E318G variant that increases the risk of 
AD in APOE-ɛ4 carriers (but possibly not relevant in the 
APOE ɛ2/3 genotype) [2], and the −48 C/T polymorphism 
in the PSEN1 promoter that is associated with an increased 
risk of AD and an increased Aβ load in the brain [37], 
which might be of relevance to the finding of sparse diffuse 
Aβ brain parenchymal deposits at 30 years of age. Overall, 
our results indicate no apparent influence of the APOE-ɛ3/4 
genotype or the apoE-4 phenotype on the presence of either 
parenchymal or vascular Aβ accumulation in the groups 
of hGH-iCJD and hGH control patients, which include a 
patient as young as 20 years of age with CAA and an apoE-
4-ve phenotype on immunohistochemistry.
Factors influencing CNS Aβ accumulation in hGH 
recipients
In considering the accumulation of Aβ in the CNS in hGH 
recipients, the assumption is that the source of the Aβ origi-
nates from Aβ deposits in the pituitary glands collected for 
hGH extraction [28, 29]. However, our investigations on 
limited numbers of non-CNS tissues yielded no evidence in 
favour of the involvement of these non-CNS tissues in the 
spread of Aβ to the CNS. In this study, no significant differ-
ences were found between the Aβ-positive and Aβ-negative 
cases in hGH recipients in terms of the time period or dura-
tion of their hGH treatment, although there was a trend for 
the hGH controls with Aβ pathology to have been treated 
in an earlier time period and for longer than the Aβ nega-
tive cases. The most severe Aβ pathology, tended to occur in 
the patients who had survived for the longest after the end of 
their hGH treatment, perhaps reflecting slowly progressive 
Aβ seeding and propagation in the CNS prior to death. The 
lack of any relationship between the duration of hGH treat-
ment and the development of Aβ pathology may be taken 
to indicate that the amount of Aβ contaminating the hGH 
inocula was variable and unpredictable. The same could 
be said for the lack of a relationship between the duration 
of hGH treatment and the development of iCJD; prion con-
tamination of the hGH inocula also having been variable and 
unpredictable.
All hGH recipients who developed iCJD in the UK, were 
treated for at least 6 months between 1967 and 1980 with 
hGH produced by the modified Wilhelmi protocol [64]. 
This study has found that all the hGH recipients with CNS 
Aβ accumulation had also been treated (for varying periods 
of time) with this same preparation. While not all patients 
treated with this preparation developed either hGH-iCJD or 
CNS Aβ accumulation, it is important to note that the four 
patients who were never treated with this hGH preparation 
did not develop either iCJD or show CNS Aβ accumulation 
(Online Resource Table 2). Subsequent studies of the hGH 
produced by the modified Wilhelmi protocol were reported 
in 1982 [63]. Using polyacrylamide gel electrophoresis 
and amino acid analysis of the high molecular weight frac-
tion of this preparation this study found “aggregated hGH 
as well as other material not separated from hGH by the 
purification procedure”. While it is highly likely that this 
“other material” included PrPSc, it may also have included 
Aβ aggregates that were neither sufficiently removed nor 
denatured by the Wilhelmi protocol for them to lose their 
capacity to act as a propagon [13].
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Questions have been raised on the clinical background 
of the patients included in the study by Jaunmuktane et al., 
suggesting that the pre-existing and underlying conditions 
causing hGH deficiency in this patient cohort “could by 
themselves lead to Aβ pathology and abnormal brain struc-
ture” [15]. In the 33 patients analysed for Aβ deposits in 
this study, we found no clinical history or neuropathologi-
cal evidence of traumatic brain injury as the cause of the 
hGH deficiency. Of the 13 hGH recipients who had brain 
tumours, three had received post-operative radiotherapy 
(Online Resource Table 2), none of whom had Aβ deposi-
tion in the CNS. In addition, no evidence of the more gen-
eralised disorders that can be associated with Aβ deposition 
in the CNS (as suggested by Feeney et al. [15]) such as 
epilepsy, fragile X syndrome, Down’s syndrome or Parkin-
son’s disease were found (Online Resource Table 2). Fur-
thermore, the morphology and distribution of Aβ lesions 
and relative lack of phospho-tau pathology argue against 
an underlying traumatic aetiology for the Aβ pathology 
reported in this study. In the two cases with incidental focal 
isolated phospho-tau pathology (pretangles and occasional 
tangles) unrelated to areas of Aβ deposition, the localised 
abnormalities did not match the recent proposed diagnostic 
criteria for chronic traumatic encephalopathy [42] and did 
not resemble the early stages of tauopathies such as corti-
cobasal degeneration [67]. In hGH control10, the accom-
panying neuronal loss and gliosis indicates longstand-
ing focal brain tissue damage that may relate to previous 
Table 3  Comparison of results with other studies on CNS Aβ accumulation in iCJD (modified from Kovacs [35])
Aβ amyloid beta, AD Alzheimer’s disease, APOE apolipoprotein E gene, CAA cerebral amyloid angiopathy, CJD Creutzfeldt–Jakob disease, 
hDM human dura mater, hGH human growth hormone, i iatrogenic, s sporadic, v variant, y years
a Cases also included in the study by Frontzek et al. [16]
b The total number of cases included in this study was 35, but two had insufficient paraffin-embedded tissue for further immunohistochemical 
analysis
Study references Jaunmuktane et al. 
[29]
Frontzek et al. [16] Kovacs et al. [36] Hamaguchi et al. 
[22]
This study
Clinical phenotype CJD CJD CJD CJD CJD Not CJD
Cause of iCJD hGH hDM hDM hDM hGH None
Number of cases 8 7 2a 16 33b 12
Other autopsy tissues 
examined
No No Yes No Yes Yes
Non-CJD autopsy 
tissues examined
Pituitary gland: 55 
cases
No Dura mater: 84 
cases
No hGH control cases—see 
Online Resources Table 4
Genetic analysis APOE + AD genes No APOE + AD genes APOE APOE + AD genes
Number with Aβ 
parenchymal 
deposits
4 + 2 focal 5 2a 13 12 4
Morphology and dis-
tribution of Aβ 
deposits described
Yes, with quantita-
tive analysis
No Yes, in detail Subpial Aβ accu-
mulation plaque 
morphology not 
included
Yes, in detail
Age of cases with 
parenchymal Aβ
5th dec-
ade—51 years
28–63 28, 33 35–81 27–45 30–45
Age of cases 
<40 years with 
parenchymal Aβ
36 (focal deposits) 28, 33 28, 33 35, 39 27–38 30–37
Number with Aβ 
CAA
3 + 1 focal 5 2a 11 14 2
Age of cases with 
Aβ CAA
5th dec-
ade—51 years
28–63 28, 33 35–81 20–37 42–45
Age of cases 
<40 years with Aβ 
CAA
None 28, 33 28–33 35–39 20–37 None
AD-related phospho-
tau pathology
No No No Yes—details given Yes—details given
Statistically sig-
nificant difference 
from sCJD
Yes Yes Yes Yes Yes—and also from vCJD
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neurosurgery. The pretangles in hGH-iCJD 31 are more 
difficult to explain, but might represent a local reaction to a 
previous focal insult no longer apparent in the post-mortem 
brain. Pretangles in the brains of very young individuals 
were identified in a large study by Braak et al. [7] in sub-
cortical sites, but not in the cerebral cortex. However, sub-
cortical pretangles or tangles were not found in this or any 
other case examined.
Aβ accumulation in the CNS has been reported in both 
hGH-iCJD cases [29] and hDM-iCJD cases [16, 22, 36]. 
However, the level of detail in these reports, varies in 
both the descriptive pathology of the CNS and the results 
of associated genetic investigations. This study adds 
considerably to these reports in terms of the number of 
cases studied, the inclusion of hGH control cases with-
out iCJD, and in the young age of the patients included. 
The detailed neuropathological description provided is 
comparable with that in Kovacs et al. [36], particularly in 
relation to the nature and localisation of the Aβ deposi-
tion and its relationship to Alzheimer’s disease, but still 
falls short of resembling a full AD neuropathological 
phenotype. Table 3 summarises the key findings in these 
reports and compares their findings with the findings in 
this study.
Conclusions and implications of results
This comprehensive study on the largest number of hGH-
iCJD cases reported to date, indicates that Aβ can behave 
as a propagon in humans, able to spread to the CNS fol-
lowing intramuscular or subcutaneous injection and sub-
sequently seed in the parenchyma of the brain and in 
cerebral blood vessels, but does not result in clinical Alz-
heimer’s disease or any other apparent clinical manifes-
tations in these patients. CNS Aβ accumulation occurred 
in around 50% of hGH-iCJD and hGH control cases, and 
is therefore not dependent on co-existing PrPSc accumu-
lation or other CJD pathology. The proposed behaviour 
of Aβ as a propagon in humans has broader implications 
including potential exposure to Aβ, for example in the re-
use of Aβ-contaminated neurosurgical instruments, previ-
ously used on the brains of elderly patients, or via blood 
transfusions from elderly donors who may have increased 
levels of plasma Aβ [3]. However, recent epidemiologi-
cal studies have found no evidence of either previous sur-
gery or blood transfusion as risk factors for Alzheimer’s 
disease [11, 68]. These findings might also be taken to 
indicate that a significant number of the remaining survi-
vors in the cohort of UK hGH recipients are at increased 
risk of CNS Aβ accumulation and, although they may not 
progress to symptomatic Alzheimer’s disease, they may 
subsequently develop vascular complications. The severe 
CAA found in the older hGH control patients in this 
study suggests that surviving hGH recipients may be at 
future risk of the complications of CAA, including spon-
taneous lobar cerebral haemorrhage, perivascular inflam-
mation and cognitive impairment [17] in addition to hav-
ing lived with the knowledge of an increased risk of CJD.
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